Disease characteristics and outcomes in younger adults with primary and secondary myelofibrosis

British Journal of Haematology

Volumn 175, Issue 1, 2016, Pages 37-42

  Beauverd, Yan ^a,b   Alimam, Samah ^a   McLornan, Donal P ^a,c   Radia, Deepti H ^a   Harrison, Claire N ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^c KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

CALR; JAK2; Myelofibrosis

Indexed keywords

ANAGRELIDE; CALRETICULIN; FEDRATINIB; HYDROXYUREA; INTERFERON; JANUS KINASE 2; RUXOLITINIB; THROMBOPOIETIN RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ADULT; ANEMIA; ARTICLE; BLOOD CELL COUNT; CALR GENE; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GENE; GENE MUTATION; HUMAN; JAK2 V617F GENE; LEUKOCYTOSIS; MALE; MPL GENE; MYELOFIBROSIS; MYELOID METAPLASIA; PHENOTYPE; POLYCYTHEMIA VERA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SECONDARY MYELOFIBROSIS; SIDE EFFECT; SPLENOMEGALY; THROMBOCYTOPENIA;

EID: 84988489872     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14173     Document Type: Article

References (16)

1. Cazzola, M. & Kralovics, R. (2014) From Janus kinase 2 to calreticulin: the clinically relevant genomic landscape of myeloproliferative neoplasms. Blood, 123, 3714–3719.
2. Cervantes, F., Dupriez, B., Pereira, A., Passamonti, F., Reilly, J.T., Morra, E., Vannucchi, A.M., Mesa, R.A., Demory, J.L., Barosi, G., Rumi, E. & Tefferi, A. (2009) New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood, 113, 2895–2901.
3. Gangat, N., Caramazza, D., Vaidya, R., George, G., Begna, K., Schwager, S., Van Dyke, D., Hanson, C., Wu, W., Pardanani, A., Cervantes, F., Passamonti, F. & Tefferi, A. (2011) DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. Journal of Clinical Oncology, 29, 392–397.
4. Guglielmelli, P., Lasho, T.L., Rotunno, G., Score, J., Mannarelli, C., Pancrazzi, A., Biamonte, F., Pardanani, A., Zoi, K., Reiter, A., Duncombe, A., Fanelli, T., Pietra, D., Rumi, E., Finke, C., Gangat, N., Ketterling, R.P., Knudson, R.A., Hanson, C.A., Bosi, A., Pereira, A., Manfredini, R., Cervantes, F., Barosi, G., Cazzola, M., Cross, N.C., Vannucchi, A.M. & Tefferi, A. (2014) The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 28, 1804–1810.
5. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of the American Statistical Association, 53, 457–481.
6. Mesa, R.A., Silverstein, M.N., Jacobsen, S.J., Wollan, P.C. & Tefferi, A. (1999) Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted County Study, 1976-1995. American Journal of Hematology, 61, 10–15.
7. Mesa, R.A., Verstovsek, S., Cervantes, F., Barosi, G., Reilly, J.T., Dupriez, B., Levine, R., Le Bousse-Kerdiles, M.C., Wadleigh, M., Campbell, P.J., Silver, R.T., Vannucchi, A.M., Deeg, H.J., Gisslinger, H., Thomas, D., Odenike, O., Solberg, L.A., Gotlib, J., Hexner, E., Nimer, S.D., Kantarjian, H., Orazi, A., Vardiman, J.W., Thiele, J. & Tefferi, A. (2007) Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leukemia Research, 31, 737–740.
8. Nangalia, J., Massie, C.E., Baxter, E.J., Nice, F.L., Gundem, G., Wedge, D.C., Avezov, E., Li, J., Kollmann, K., Kent, D.G., Aziz, A., Godfrey, A.L., Hinton, J., Martincorena, I., Van Loo, P., Jones, A.V., Guglielmelli, P., Tarpey, P., Harding, H.P., Fitzpatrick, J.D., Goudie, C.T., Ortmann, C.A., Loughran, S.J., Raine, K., Jones, D.R., Butler, A.P., Teague, J.W., O'Meara, S., McLaren, S., Bianchi, M., Silber, Y., Dimitropoulou, D., Bloxham, D., Mudie, L., Maddison, M., Robinson, B., Keohane, C., Maclean, C., Hill, K., Orchard, K., Tauro, S., Du, M.Q., Greaves, M., Bowen, D., Huntly, B.J., Harrison, C.N., Cross, N.C., Ron, D., Vannucchi, A.M., Papaemmanuil, E., Campbell, P.J. & Green, A.R. (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. New England Journal of Medicine, 369, 2391–2405.
9. Pardanani, A., Tefferi, A., Jamieson, C., Gabrail, N.Y., Lebedinsky, C., Gao, G., Liu, F., Xu, C., Cao, H. & Talpaz, M. (2015) A phase 2 randomized dose-ranging study of the JAK2-selective inhibitor fedratinib (SAR302503) in patients with myelofibrosis. Blood Cancer J, 5, e335.
10. Passamonti, F., Cervantes, F., Vannucchi, A.M., Morra, E., Rumi, E., Pereira, A., Guglielmelli, P., Pungolino, E., Caramella, M., Maffioli, M., Pascutto, C., Lazzarino, M., Cazzola, M. & Tefferi, A. (2010) A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood, 115, 1703–1708.
11. Rumi, E., Pietra, D., Pascutto, C., Guglielmelli, P., Martinez-Trillos, A., Casetti, I., Colomer, D., Pieri, L., Pratcorona, M., Rotunno, G., Sant'Antonio, E., Bellini, M., Cavalloni, C., Mannarelli, C., Milanesi, C., Boveri, E., Ferretti, V., Astori, C., Rosti, V., Cervantes, F., Barosi, G., Vannucchi, A.M. & Cazzola, M.; Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators. (2014) Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis. Blood, 124, 1062–1069.
12. Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., Thiele, J. & Vardiman, J. (2008) WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, 4th edn. International Agency for Research on Cancer Press, Lyon, France.
13. Tefferi, A., Guglielmelli, P., Larson, D.R., Finke, C., Wassie, E.A., Pieri, L., Gangat, N., Fjerza, R., Belachew, A.A., Lasho, T.L., Ketterling, R.P., Hanson, C.A., Rambaldi, A., Finazzi, G., Thiele, J., Barbui, T., Pardanani, A. & Vannucchi, A.M. (2014a) Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood, 124, 2507–2513; quiz 2615.
14. Tefferi, A., Lasho, T.L., Finke, C.M., Knudson, R.A., Ketterling, R., Hanson, C.H., Maffioli, M., Caramazza, D., Passamonti, F. & Pardanani, A. (2014b) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia, 28, 1472–1477.
15. Vannucchi, A.M., Guglielmelli, P., Rotunno, G., Pascutto, C., Pardanani, A., Ferretti, V., Pacilli, A., Pancrazzi, A., Lasho, T., Hanson, C.A., Ketterling, R., Gangat, N., Tagliafico, E., Manfredini, R., Artusi, V., Bernardis, I., Pietra, D., Rumi, E., Maffioli, M., Rosti, V., Salmoiraghi, S., Delaini, F., Bosi, A., Cilloni, D., Cervantes, F., Passamonti, F., Barosi, G., Rambaldi, A., Barbui, T., Cazzola, M. & Tefferi, A. (2014) Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: an AGIMM & IWG-MRT Project. Blood, 124, 405–405.
16. Visani, G., Finelli, C., Castelli, U., Petti, M.C., Ricci, P., Vianelli, N., Gianni, L., Zuffa, E., Aloe Spiriti, M.A., Latagliata, R., Pileri, S., Magrini, U., Gugliotta, L., Morra, E., Bernasconi, C., Mandelli, F. & Tura, S. (1990) Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients. British Journal of Haematology, 75, 4–9.